| 3VZV: reference: Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold., Miyazaki M, Naito H, Sugimoto Y, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Aonuma M, Soga T, Bioorg Med Chem Lett. 2013 Feb 1;23(3):728-32. doi: 10.1016/j.bmcl.2012.11.091., Epub 2012 Dec 1. PMID: 23266121 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).